<i>Conclusions</i>: The pre-treatment PET SUVmax/albumin ratio was significantly associated with PFS in patients with gastric cancer treated with neoadjuvant FLOT and may represent an exploratory composite prognostic biomarker requiring further prospective validation. Here, ALB is linked to gastric cancer.